Oisin Biotechnologies

About:

Oisin Biotechnologies is a drug development company focused on mitigating the senolytic technology to combat age-related diseases.

Website: https://www.oisinbio.com

Top Investors: AbbVie, Hedgewood, KIZOO Technology Capital, Avant Global, Kingsley Advani

Description:

Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age-related diseases. It is developing a highly precise, patent-pending, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces the negative effects of aging pathologies and also extends the median lifespan and survival. Oisin Biotechnologies was founded in 2014 and is headquartered in Seattle, Washington.

Total Funding Amount:

$22.1M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Seattle, Washington, United States

Founded Date:

2014-01-01

Founders:

Garry Hudson, Kevin Perrott, Matthew Scholz

Number of Employees:

11-50

Last Funding Date:

2024-07-24

IPO Status:

Private

Industries:

© 2025 bioDAO.ai